Wikipedia -WSS

Wikipedia

author：focus 2025-09-30 09:03:26 - browse：91

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： 'The Exorcist' director William Friedkin dead at 87

knowledge

WSS

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Boston hospital trains restaurant workers on naloxone for overdoses

HHS suspends federal funding for EcoHealth Alliance

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Illinois to ban advertising for guns allegedly marketed to kids and militants

explore

Wikipedia

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Biden will tout long

Hollywood unions extend contract negotiations for actors

Biden will tout long

Wildfire smoke exposes gaps in outdoor worker protections

ALS treatment from Biogen, Ionis fails in study

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Illinois to ban advertising for guns allegedly marketed to kids and militants

The cancer drug shortage isn’t new — and neither are the solutions

Trump Jan. 6 attorney John Lauro is ex

leisure time

Fertility clinic egg and embryo storage is a disaster

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Obesity drug from Roche shows promise in early study

Mississippi candidates for statewide offices square off in party primaries

The United States must get value

knowledge

explore

explore

Wikipedia